Oriol Mirallas, Clinical Fellow in the Investigational Cancer Therapeutics (ICT) Department at the University of Texas MD Anderson Cancer Center, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“I am thrilled to share that we have published our first meta-analysis at Society for Immunotherapy of Cancer (SITC)
Greatly led by my colleague and friend Pablo Jimenez Labaig together with Ana Isabel Martin Quesada
Key points from this meta analysis
- 34,973 patients
- 47 RCT analyzed
Early use of anti-PD-(L)1 was associated with improved EFS2/PRFS2/PFS2 compared with non-anti-PD-(L)1 arms, while delayed immunotherapy use in control arms was linked to worse outcomes
EFS2/PRFS2/PFS2 correlated with overall survival (R² 0.74) meaningfully outperforming first-event endpoints (EFS/DFS/PFS) R² 0.39
This study supports early use of PD1 PDL1 in treatment sequencing
PFS2 should be considered as an endpoint in clinical trials to better capture long-term effects of immunotherapy
Thanks for the feedback and support from Toni Rullan, Teresa Amaral, Dario Trapani, Enriqueta Felip, Josep Tabernero, and Kevin Harrington”
Title: Second- event endpoints (EFS2, PRFS2 and PFS2) after anti- PD- (L)1- based RCTs: a systematic review and meta-analysis
Authors: Pablo Jimenez, Oriol Mirallas, Ana Martin Quesada, Antonio Rullan, Dario Trapani, Teresa Amaral, Enriqueta Felip, Josep Tabernero, Kevin J Harrington
Read the Full Article on Society for Immunotherapy of Cancer
More posts featuring Oriol Mirallas
